LADENBURG THALMANN FINANCIAL SERVICES INC. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2019$0
-100.0%
182
-96.5%
0.00%
Q3 2019$5,0005,2550.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$40,874,5173.42%
Defender Capital, LLC. 5,093,535$5,959,4362.41%
Raffles Associates 1,536,946$1,798,2302.10%
Prescott General Partners LLC 1,851,851$2,166,6660.18%
DAFNA Capital Management LLC 140,000$163,8000.05%
Fort Sheridan Advisors LLC 83,931$98,1990.03%
Beirne Wealth Consulting Services, LLC 45,000$52,6500.03%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$914,6660.02%
ETF MANAGERS GROUP, LLC 353,991$414,1690.02%
Straight Path Wealth Management 16,200$18,9540.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders